Search | Clinical Trials Finder

Conditions: Mantle Cell Lymphoma
Interventions: Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more

Conditions: Autism Spectrum Disorder, Language Disorders
Interventions: Levoleucovorin Calcium, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 30 Months to 60 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions: Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions; Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 2 Months to 6 Months
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: bortezomib, cyclophosphamide, lenalidomide, laboratory biomarker analysis, dexamethasone, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Scottsdale, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 7-hydroxystaurosporine, fluorouracil, leucovorin calcium; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hypertension
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Overland Park, Kansas • Willingboro, New Jersey

Conditions: Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Angelman Syndrome
Interventions: minocycline; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 12 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Post-Operative Nausea and Vomiting, Breast Cancer
Interventions: Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire; Procedure · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate; Drug · Device · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Statin Therapy, Statin Adverse Reaction, Statin
Interventions: Rosuvastatin (Crestor), Placebo; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: NEUROBLASTOMA
Interventions: Zolendric acid, Cyclophosphamide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 30 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 5 more

Conditions: Multiple Myeloma
Interventions: ACE-011, Lenalidomide, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten, Non-mavacamten symptomatic oHCM therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 60
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: Obesity, Overweight
Interventions: Orange Juice fortified with Calcium and Vitamin D, Orange juice without Ca or VitD, Nutritional Counseling; Dietary Supplement · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumour
Interventions: HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor; Drug
Lead sponsor: Henlix, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fremont, California

Conditions: Osteoporosis, Prostate Cancer
Interventions: Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D; Dietary Supplement · Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 80
States / cities: Chico, California • Los Angeles, California • Pomona, California + 66 more

Conditions: Postmenopausal, Vitamin D Deficiency
Interventions: Dual isotope technique; Other
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Pneumonia
Interventions: CM4620-IE (Injectable Emulsion), Placebo; Drug
Lead sponsor: CalciMedica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye
Interventions: Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain and Central Nervous System Tumors, Lymphoma
Interventions: rituximab, methotrexate, temozolomide 100 mg/m^2, temozolomide 150 mg/m^2, temozolomide 200 mg/m^2, radiation therapy, post-radiation therapy temozolomide; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 26
States / cities: Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more

Conditions: Vitamin D Insufficiency
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Minocycline in the Treatment of Angelman Syndrome

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

DESIFOR-EXPAND (MHIF)

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Calcium Supplementation for a Healthy Weight (CaSHeW)

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

Study to Observe the Capability to Absorb Calcium as an Measure of Adequate Levels of Vitamin D

A Study of Auxora in Patients With Critical COVID-19 Pneumonia

Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages